Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equipment, Net

Equipment, Net

9 Months Ended

Sep. 30, 2013

6. Equipment, Net



	September 30,		December 31,
	2013		2012

Furniture and fixtures	$	58,171	$	34,200
Office equipment		39,024		81,074
Lab and computer equipment		425,195		430,261
Leasehold improvements		119,841		119,841

Total fixed assets		642,231		665,376
Less: Accumulated depreciation		(571,812)		(613,220)

Net carrying amount	$	70,419	$	52,156

Depreciation expense was $9,645 and $10,721 for the three months ended September 30, 2013 and 2012, respectively, and $28,196 and $32,163 for the nine months ended September 30, 2013 and 2012, respectively.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details